한글목차

저분자 암 표적치료 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 853억 5,000만 달러에서 2026년에는 931억 7,000만 달러에 이르고, CAGR 9.2%로 성장할 전망입니다. 지난 수년간의 성장에는 암 발생률 증가, 분자 종양학 경로에 대한 이해의 심화, 표적치료제 발굴 프로그램의 확대, 1세대 표적 억제제의 규제 당국 승인, 종양학 연구에 대한 투자 증가 등이 주요 요인으로 꼽힙니다.

저분자 암 표적치료 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 1,309억 달러에 이르고, CAGR은 8.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 개인 맞춤형 암 치료 도입 확대, 차세대 억제제 개발 증가, 동반진단제 사용 확대, 내성 관리 전략에 대한 집중 강화, 암 치료제 파이프라인 활동 활성화 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 돌연변이 특이적 억제제 개발 증가, 정밀 종양학 치료의 도입 확대, 경구용 저분자 약물에 대한 관심 증가, 병용 표적 치료 요법의 확대, 바이오마커에 기반한 치료 선택에 대한 중요성 강화 등을 꼽을 수 있습니다.

개인 맞춤형 의료에 대한 수요 증가는 향후 몇 년 동안 저분자 표적치료제 시장의 성장을 견인할 것으로 예측됩니다. 맞춤형 의료는 환자 개개인의 고유한 특성에 따라 질병의 예방, 진단, 치료를 맞춤화하는 의료 접근법입니다. 효능을 높이고 부작용을 줄이는 표적치료에 대한 수요가 증가함에 따라 개인 맞춤형 의료에 대한 수요가 증가하고 있습니다. 저분자 표적치료제는 치료의 특이성을 높이고, 환자의 반응을 높이며, 부작용을 최소화하고, 개인의 유전적, 분자적 프로파일에 맞는 치료를 가능하게 함으로써 맞춤의료를 뒷받침하고 있습니다. 예를 들어, 2024년 2월 미국 비영리단체 '맞춤의료연합'이 발표한 바에 따르면, 미국 식품의약국(FDA)은 2023년 희귀질환 환자를 위한 16개의 새로운 맞춤치료제를 승인했습니다. 이는 2022년 6건에서 크게 증가한 수치입니다. 이러한 개인 맞춤형 의료에 대한 수요 증가는 저분자 표적치료제 시장의 성장을 가속하고 있습니다.

유방암 저분자 표적치료제 시장에서 사업을 전개하고 있는 주요 기업들은 치료 효과를 높이고 특정 암세포 신호전달 경로를 보다 정밀하게 표적화하기 위해 PI3K 억제제, CDK4/6 억제제 병용요법 등 첨단 치료법 개발에 집중하고 있습니다. PI3K 억제제는 종양의 증식과 생존에 관여하는 포스파티딜 이노시톨 3 키나아제 경로를 억제하는 표적치료제이며, CDK4/6 억제제 병용요법은 호르몬 수용체 양성 암세포에서 세포주기의 진행을 특이적으로 멈추게 하는 표적치료제입니다. 예를 들어, 2024년 10월 미국 바이오기업 제넨텍(Genentech)은 성인 환자에서 인보리시브(이토벨비)와 파보시클립(이브란세), 플루베스트란트(파슬로덱스)의 병용요법에 대해 FDA의 승인을 받았습니다. 미국 식품의약국(FDA)으로부터 PIK3CA 돌연변이가 있는 호르몬 수용체 양성, HER2 음성 내분비요법 내성, 국소 진행성 또는 전이성 성인 유방암 환자에 대한 인보리시브(이토벨비)와 파보시클립(이브란스), 플루베스트란트(파슬로덱스)의 병용요법 승인을 획득했습니다. 승인을 획득하였습니다. 이번 승인은 단독요법(팔보시클립+플루베스트란트) 대비 무진행생존기간 및 객관적 반응률에서 유의미한 개선을 보인 INAVO120 임상결과를 근거로 하고 있습니다. 이는 HR 양성 및 HER2 음성 유방암에서 개인 맞춤형 치료의 중요한 진전이며, PIK3CA 돌연변이가 있는 환자들에게 표적 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Small molecule targeted cancer therapy is a form of cancer treatment that employs low-molecular-weight compounds to selectively target proteins or pathways in cancer cells, blocking tumor growth while limiting harm to healthy cells. Its goal is to offer precise, effective, and personalized treatment options that enhance patient outcomes and lessen the side effects linked to traditional chemotherapy.

The main therapy types of small molecule targeted cancer therapy comprise tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, PARP inhibitors, CDK inhibitors, BCL-2 inhibitors, mTOR inhibitors, and others. Tyrosine kinase inhibitors are targeted compounds developed to block specific enzymes involved in cancer cell growth and proliferation, delivering precise therapeutic effects with minimized systemic toxicity. These therapies are applied in various cancer types, including lung cancer, breast cancer, colorectal cancer, leukemia, prostate cancer, and others. They are administered orally, intravenously, and via other routes, distributed through hospital pharmacies, retail pharmacies, online pharmacies, and direct sales, with primary end-users including hospitals, specialty clinics, research institutes, and others.

Tariffs are impacting the small molecule targeted cancer therapy market by increasing costs of imported active pharmaceutical ingredients, intermediates, specialized reagents, and manufacturing equipment used in drug synthesis and formulation. North America and Europe are most affected due to reliance on global API supply chains, while Asia-Pacific faces cost pressures linked to export-oriented pharmaceutical manufacturing. These tariffs are increasing production expenses and influencing pricing strategies for targeted therapies. However, they are also encouraging localization of API manufacturing, diversification of supplier networks, and increased investment in domestic pharmaceutical production infrastructure, supporting long-term supply chain resilience.

The small molecule targeted cancer therapy market research report is one of a series of new reports from The Business Research Company that provides small molecule targeted cancer therapy market statistics, including small molecule targeted cancer therapy industry global market size, regional shares, competitors with a small molecule targeted cancer therapy market share, detailed small molecule targeted cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule targeted cancer therapy industry. This small molecule targeted cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule targeted cancer therapy market size has grown strongly in recent years. It will grow from $85.35 billion in 2025 to $93.17 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising cancer incidence rates, increased understanding of molecular oncology pathways, expansion of targeted drug discovery programs, regulatory approvals of first-generation targeted inhibitors, growing investment in oncology research.

The small molecule targeted cancer therapy market size is expected to see strong growth in the next few years. It will grow to $130.9 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing adoption of personalized cancer medicine, rising development of next-generation inhibitors, expansion of companion diagnostics usage, growing focus on resistance management strategies, increasing oncology drug pipeline activity. Major trends in the forecast period include increasing development of mutation-specific inhibitors, rising adoption of precision oncology therapies, growing focus on oral small molecule drugs, expansion of combination targeted therapy regimens, enhanced emphasis on biomarker-driven treatment selection.

The increasing demand for personalized medicine is expected to drive the growth of the small molecule targeted therapy market in the coming years. Personalized medicine is a medical approach that customizes the prevention, diagnosis, and treatment of diseases according to the unique characteristics of each patient. The demand for personalized medicine is rising due to the growing need for targeted therapies that enhance effectiveness and reduce adverse effects. Small molecule targeted therapy supports personalized medicine by improving treatment specificity, enhancing patient response, minimizing side effects, and enabling therapies tailored to individual genetic and molecular profiles. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the growth of the small molecule targeted therapy market.

Major companies operating in the breast cancer small-molecule targeted therapy market are concentrating on developing advanced therapies such as PI3K inhibitors and CDK4/6 inhibitor combinations to improve treatment outcomes and more precisely target specific cancer cell signaling pathways. PI3K inhibitors are targeted therapies that block the phosphatidylinositol-3-kinase pathway, which plays a role in tumor growth and survival, while CDK4/6 inhibitor combinations are designed to specifically stop cell cycle progression in hormone receptor-positive cancer cells. For example, in October 2024, Genentech, Inc., a US-based biotechnology company, obtained approval from the U.S. Food and Drug Administration (FDA) for inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced, or metastatic breast cancer. The approval was based on the results of the INAVO120 trial, which showed a significant improvement in progression-free survival and objective response rate compared to palbociclib and fulvestrant alone. This represents a significant advancement in personalized therapy for HR-positive, HER2-negative breast cancer, providing a targeted treatment option for patients with PIK3CA mutations.

In May 2023, Gilead Sciences, Inc., a US-based biopharmaceutical company, acquired XinThera Inc. for an undisclosed sum. Through this acquisition, Gilead Sciences intends to enhance its oncology and inflammation pipeline by incorporating XinThera's small molecule inhibitors targeting PARP1 and MK2, broadening its range of precision medicines. XinThera Inc. is a US-based biotechnology company focused on developing small molecule therapies for oncology and immunology.

Major companies operating in the small molecule targeted cancer therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc.

North America was the largest region in the small molecule targeted cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule targeted cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule targeted cancer therapy market consists of sales of novel agents, venetoclax, imatinib, olaparib, niraparib. Values in this market are 'factory gate' values, meaning the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market also includes related services provided by the creators of these therapies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Targeted Cancer Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses small molecule targeted cancer therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small molecule targeted cancer therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small molecule targeted cancer therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy Type: Tyrosine Kinase Inhibitors; Proteasome Inhibitors; Histone Deacetylase Inhibitors; PARP Inhibitors; CDK Inhibitors; BCL-2 Inhibitors; mTOR Inhibitors; Other Small Molecule Inhibitors
• 2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Cancer Types
• 3) By Mode Of Administration: Oral; Intravenous; Other Modes
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Direct Sales
• 5) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
• Subsegments:
• 1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors; VEGFR Inhibitors; ALK Inhibitors; BCR-ABL Inhibitors; HER2 Inhibitors
• 2) By Proteasome Inhibitors: Bortezomib; Carfilzomib; Ixazomib
• 3) By Histone Deacetylase Inhibitors: Pan-Histone Deacetylase Inhibitors; Class-specific Histone Deacetylase Inhibitors
• 4) By PARP Inhibitors: Olaparib; Niraparib; Rucaparib; Talazoparib
• 5) By CDK Inhibitors: CDK4/6 Inhibitors; CDK1/2 Inhibitors; Pan-CDK Inhibitors
• 6) By BCL-2 Inhibitors: Venetoclax; Navitoclax
• 7) By mTOR Inhibitors: Rapamycin Analogs (Rapalogs); ATP-competitive mTOR Inhibitors; Dual mTOR/PI3K Inhibitors
• 8) By Other Small Molecule Inhibitors: MEK Inhibitors; PI3K Inhibitors; RAF Inhibitors
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Novartis International AG; AstraZeneca plc; Bristol-Myers Squibb Company; GlaxoSmithKline plc (GSK); Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Ipsen Biopharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Small Molecule Targeted Cancer Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Small Molecule Targeted Cancer Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Small Molecule Targeted Cancer Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Small Molecule Targeted Cancer Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Development Of Mutation-Specific Inhibitors
  • 4.2.2 Rising Adoption Of Precision Oncology Therapies
  • 4.2.3 Growing Focus On Oral Small Molecule Drugs
  • 4.2.4 Expansion Of Combination Targeted Therapy Regimens
  • 4.2.5 Enhanced Emphasis On Biomarker-Driven Treatment Selection

5. Small Molecule Targeted Cancer Therapy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Centers
• 5.3 Specialty Clinics
• 5.4 Research Institutes
• 5.5 Pharmaceutical Companies

6. Small Molecule Targeted Cancer Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Small Molecule Targeted Cancer Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Small Molecule Targeted Cancer Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Small Molecule Targeted Cancer Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Small Molecule Targeted Cancer Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Small Molecule Targeted Cancer Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Small Molecule Targeted Cancer Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Small Molecule Targeted Cancer Therapy Market Segmentation

• 9.1. Global Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, PARP Inhibitors, CDK Inhibitors, BCL-2 Inhibitors, mTOR Inhibitors, Other Small Molecule Inhibitors
• 9.2. Global Small Molecule Targeted Cancer Therapy Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Cancer Types
• 9.3. Global Small Molecule Targeted Cancer Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Other Modes
• 9.4. Global Small Molecule Targeted Cancer Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Sales
• 9.5. Global Small Molecule Targeted Cancer Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Research Institutes, Other End Users
• 9.6. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• EGFR Inhibitors, VEGFR Inhibitors, ALK Inhibitors, BCR-ABL Inhibitors, HER2 Inhibitors
• 9.7. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of Proteasome Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bortezomib, Carfilzomib, Ixazomib
• 9.8. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of Histone Deacetylase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pan-Histone Deacetylase Inhibitors, Class-specific Histone Deacetylase Inhibitors
• 9.9. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of PARP Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Olaparib, Niraparib, Rucaparib, Talazoparib
• 9.10. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of CDK Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• CDK4/6 Inhibitors, CDK1/2 Inhibitors, Pan-CDK Inhibitors
• 9.11. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of BCL-2 Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Venetoclax, Navitoclax
• 9.12. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of mTOR Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rapamycin Analogs (Rapalogs), ATP-competitive mTOR Inhibitors, Dual mTOR/PI3K Inhibitors
• 9.13. Global Small Molecule Targeted Cancer Therapy Market, Sub-Segmentation Of Other Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• MEK Inhibitors, PI3K Inhibitors, RAF Inhibitors

10. Small Molecule Targeted Cancer Therapy Market Regional And Country Analysis

• 10.1. Global Small Molecule Targeted Cancer Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Small Molecule Targeted Cancer Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Small Molecule Targeted Cancer Therapy Market

• 11.1. Asia-Pacific Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Small Molecule Targeted Cancer Therapy Market

• 12.1. China Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Small Molecule Targeted Cancer Therapy Market

• 13.1. India Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Small Molecule Targeted Cancer Therapy Market

• 14.1. Japan Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Small Molecule Targeted Cancer Therapy Market

• 15.1. Australia Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Small Molecule Targeted Cancer Therapy Market

• 16.1. Indonesia Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Small Molecule Targeted Cancer Therapy Market

• 17.1. South Korea Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Small Molecule Targeted Cancer Therapy Market

• 18.1. Taiwan Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Small Molecule Targeted Cancer Therapy Market

• 19.1. South East Asia Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Small Molecule Targeted Cancer Therapy Market

• 20.1. Western Europe Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Small Molecule Targeted Cancer Therapy Market

• 21.1. UK Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Small Molecule Targeted Cancer Therapy Market

• 22.1. Germany Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Small Molecule Targeted Cancer Therapy Market

• 23.1. France Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Small Molecule Targeted Cancer Therapy Market

• 24.1. Italy Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Small Molecule Targeted Cancer Therapy Market

• 25.1. Spain Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Small Molecule Targeted Cancer Therapy Market

• 26.1. Eastern Europe Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Small Molecule Targeted Cancer Therapy Market

• 27.1. Russia Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Small Molecule Targeted Cancer Therapy Market

• 28.1. North America Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Small Molecule Targeted Cancer Therapy Market

• 29.1. USA Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Small Molecule Targeted Cancer Therapy Market

• 30.1. Canada Small Molecule Targeted Cancer Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Small Molecule Targeted Cancer Therapy Market

• 31.1. South America Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Small Molecule Targeted Cancer Therapy Market

• 32.1. Brazil Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Small Molecule Targeted Cancer Therapy Market

• 33.1. Middle East Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Small Molecule Targeted Cancer Therapy Market

• 34.1. Africa Small Molecule Targeted Cancer Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Small Molecule Targeted Cancer Therapy Market, Segmentation By Therapy Type, Segmentation By Cancer Type, Segmentation By Mode Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Small Molecule Targeted Cancer Therapy Market Regulatory and Investment Landscape

36. Small Molecule Targeted Cancer Therapy Market Competitive Landscape And Company Profiles

• 36.1. Small Molecule Targeted Cancer Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Small Molecule Targeted Cancer Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Small Molecule Targeted Cancer Therapy Market Company Profiles
  • 36.3.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Small Molecule Targeted Cancer Therapy Market Other Major And Innovative Companies

• Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc.

38. Global Small Molecule Targeted Cancer Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Small Molecule Targeted Cancer Therapy Market

40. Small Molecule Targeted Cancer Therapy Market High Potential Countries, Segments and Strategies

• 40.1 Small Molecule Targeted Cancer Therapy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Small Molecule Targeted Cancer Therapy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Small Molecule Targeted Cancer Therapy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer